Glimpor (Glimepiride)

Glimpor is indicated for the oral treatment of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• As monotherapy in patients newly diagnosed with type 2 diabetes.
• In combination with metformin when metformin alone does not achieve target glucose levels.
• As part of a fixed‑dose combination with other oral antidiabetic agents, if clinically appropriate.
• To improve fasting and post‑prandial blood glucose concentrations as directed by a healthcare professional.

The safety profile of Glimpor reflects the typical adverse events associated with sulfonylureas, ranging from mild, frequently reported symptoms to rare but serious conditions.

Common

• Mild hypoglycemia, especially if meals are skipped or delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Headache or dizziness that may occur during treatment initiation.
• Skin reactions like mild rash or pruritus.
• Weight gain or increased appetite observed in some patients.

Serious

• Severe hypoglycemia leading to confusion, loss of consciousness, or seizures.
• Allergic reactions including angioedema, bronchospasm, or anaphylaxis.

When prescribing Glimpor, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

• Assess renal and hepatic function before initiating therapy and periodically thereafter.
• Review history of cardiovascular disease, as sulfonylureas may affect cardiac outcomes.
• Caution in elderly patients due to higher susceptibility to hypoglycemia.
• Avoid use in patients with known hypersensitivity to glimepiride or other sulfonylureas.
• Counsel patients on recognizing signs of low blood sugar and the importance of regular meals.
• Monitor blood glucose regularly to adjust dose and prevent prolonged hypoglycemia.

Glimpor may interact with several medications that alter glucose metabolism or affect sulfonylurea clearance, requiring dose adjustments or monitoring.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemic effect.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which may increase glimepiride plasma concentrations.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may impair glucose tolerance and require closer monitoring.
• Alcohol consumption, which can potentiate hypoglycemia, especially when taken with meals.
• Anticoagulants such as warfarin, as hypoglycemia can affect INR stability.
• ACE inhibitors, which may enhance insulin sensitivity and require periodic glucose monitoring.